OOIR: Observatory of International Research

Papers

(The TQCC of Current Opinion in HIV and AIDS is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
Editorial introductions	113
Integrating socio-behavioral, ethics, community, and translational science considerations in HIV cure research	78
Recent advances on anti-HIV chimeric antigen receptor-T-cell treatment to provide sustained HIV remission	51
The sounds of silencing: dynamic epigenetic control of HIV latency	34
Updates on bone health in people living with HIV: global impact, prediction tools, and treatment	30
Future options for long-acting HIV treatment and prevention	28
Harnessing natural killer cells to target HIV-1 persistence	28
HIV-associated tuberculosis in infants, children, and adolescents younger than 15 years: an update on the epidemiology, diagnosis, prevention, and treatment	27
Advancing HIV cure: insights from developing chronic hepatitis b therapies for functional cure	26
Impact of early antiretroviral therapy, early life immunity and immune sex differences on HIV disease and posttreatment control in children	26
Statins for primary cardiovascular disease prevention among people with HIV: emergent directions	26
A behavioral economics approach to enhancing HIV preexposure and postexposure prophylaxis implementation	25
Editorial introduction	25
Editorial introduction	24
Fc-mediated immunological mechanisms in HIV infection: a better understanding for improved therapeutic approaches	20
New latency-promoting agents for a block-and-lock functional cure strategy	20
Loneliness and social isolation in people with HIV	20
Editorial introduction	18
Pulse check: modern strategies for cardiovascular risk in women with detection and prevention in women with HIV	18
Challenges towards an AIDS-free generation in Africa and Asia	18
Development of screening assays for use of broadly neutralizing antibodies in people with HIV	17
Persistent elite controllers as the key model to identify permanent HIV remission	16
Balancing polypharmacy and comorbidity management: cardiovascular health	14
Current insight into HIV-1 persistence from single-cell transcriptome profiling in acutely treated cohorts of infection	14
The origins of new SARS-COV-2 variants in immunocompromised individuals	14

Impact of coronavirus disease 2019 on co-morbidities in HIV	13
Defining multimorbidity in people with HIV – what matters most?	13
Integrating substance use services into HIV care: an underused implementation science opportunity	13
Editorial introduction	13
Viral and immune predictors of HIV posttreatment control	13
New vector and vaccine platforms: mRNA, DNA, viral vectors	13
Role of follicular homing natural killer cells in HIV infection	13
Aging of adult lifetime survivors with perinatal HIV	12
Mpox and the impact on people with HIV	12
The multifaceted nature of HIV tissue reservoirs	12
Hepatitis co-infection in paediatric HIV: progressing treatment and prevention	12
Single-cell multiomic understanding of HIV-1 reservoir at epigenetic, transcriptional, and protein levels	11
Frailty in people with HIV: a geriatric syndrome approach to aging with HIV	11
Obesity among women with HIV	11
Gender and sex considerations in HIV and bone health	11
Broadly neutralizing antibodies for HIV treatment and cure approaches	11
Metabolic dysfunction-associated steatotic liver disease in people with HIV	11
Beyond criminalization: reconsidering HIV criminalization in an era of reform	10
Host factors predisposing to kidney disease in people with HIV	10
Single-cell sequencing technologies: a multiomics toolbox for investigating HIV-1 persistence	10
Editorial: New drugs for HIV: quo vadis?	10
Roadmap for spatial transcriptomics of HIV in tissues	10
Use of implementation theories, models, and frameworks in PrEP implementation research from 2022–2025: innovation and participation	9
Maintain the gains: methods to evaluate the sustainability and scalability of HIV-related prevention, care, and treatment programs	9
The severity of COVID-19 across the spectrum of HIV	9
Editorial introduction	8
Editorial introductions	8
Strategies to target the central nervous system HIV reservoir	8
Harnessing innate immunity: natural killer cells and innate immune responses in reservoir clearance	8
Innovative models of care supporting people aging with HIV	8
HIV and cardiovascular disease: the role of inflammation	8
Vaccinal effect of HIV-1 antibody therapy: dream or reality?	7
CD8+ T-cell responses in HIV controllers: potential implications for novel HIV remission strategies	7
Causes and outcomes of hepatic fibrosis in persons living with HIV	7
Editorial: Is it time to implement injectable antiretroviral treatments globally?	7
Persistent HIV-1 transcription during ART: time to reassess its significance?	7
Contemporary issues in gynecologic and reproductive health for women with HIV	7
The pathogenesis of obesity in people living with HIV	7
HIV drug resistance in various body compartments	7
Editorial introductions	6
Editorial introductions	6
Progress with induction of HIV broadly neutralizing antibodies in the Duke Consortia for HIV/AIDS Vaccine Development	6
Editorial introduction	6
Guiding HIV-1 vaccine development with preclinical nonhuman primate research	6
How could HIV-1 drug resistance impact preexposure prophylaxis for HIV prevention?	6
HIV-1 subtypes and latent reservoirs	6
The role of analytical treatment interruptions in shaping HIV-specific immunity and HIV cure	6
Adolescents and young adults with HIV and unsuppressed viral load: where do we go from here?	6